** Shares of SpringWorks Therapeutics rise 2.5% to $42.1
** Co says the U.S. Food and Drug Administration has granted Priority Review to its application seeking approval for its experimental drug to treat NF1-PN in adult and pediatric patients
** NF1-PN is a rare genetic disorder characterized by changes in skin coloring and the growth of tumors along nerves in the skin, brain and other parts of the body
** FDA is set to make a decision on the drug, mirdametinib, by February 28, 2025 - SWTX
** FDA is not currently planning to hold an advisory committee meeting to discuss the application - SWTX
** Including session moves, stock had risen 13.3% YTD
(Reporting by Mariam Sunny in Bengaluru)
((Mariam.ESunny@thomsonreuters.com;))
Comments